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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.04.001Plasma cell leukemia (PCL) is a rare hematologic malignancy with very poor outcome. It is defined by the pres-
ence of >2 · 109/L plasma cells or >20% plasmacytosis of the differential white cell count in the peripheral
blood. Primary PCL is first diagnosed in the leukemic phase, while secondary PCL corresponds to the leukemic
transformation of a previously diagnosed multiple myeloma (MM). The incidence of PCL ranges between 2–4%
of patients with MM and 0.9% of patients with acute leukemia. In this case series, we describe the clinicopatho-
logic, immunophenotypic, and cytogenetic findings of four patients diagnosed with PCL within a ten-year period
(2002–2012) at King Faisal Specialist Hospital and Research Centre (General Organization), Riyadh, Saudi
Arabia.
KEYWORDS: Leukemia; Plasma cell; Plasma cell leukemia; Multiple myelomaPlasma cell leukemia (PCL) is deﬁned by thepresence of more than 2 · 109/L peripheralblood plasma cells (PC) or plasmacytosis
accounting for >20% of the differential white cell
count.1 Primary PCL is malignant PC proliferation
that is ﬁrst diagnosed in the leukemic phase, while
secondary PCL corresponds to the leukemic transfor-
mation of a previously diagnosed multiple myeloma
(MM).2,3 The prognosis of PCL is very poor, with
a median overall survival (OS) of only seven months.4
Due to the rarity of the disease, pathologic ﬁndings
are not well described in the literature. In this case
series we describe the clinicopathologic, immunophe-
notypic, and cytogenetic ﬁndings for four cases diag-
nosed with PCL within the period of 10 years
(2002–2012) at King Faisal Specialist Hospital and
Research Centre (General Organization), Riyadh,
Saudi Arabia.CASES REPORT
Case 1
A 52-year-old male patient was initially referred for
evaluation and treatment of MM. He was known to
have bipolar disorder and initially diagnosed as a case
of stage III IgG kappa MM. He presented with renal
impairment, for which he was started on dexametha-
sone with a good response. Later on, the patient was
started on thalidomide 100 mg orally every other day
in addition to dexamethasone as an induction treat-
ment. Unfortunately after two cycles, he developed
dexamethasone-induced psychosis and he was kept
on thalidomide at a dose of 150 mg/d. Because of
suboptimal response he was started on Velcade but
there was no improvement, and therefore, dexametha-
sone was added. He completed four cycles but unfor-
tunately the disease was refractory and his laboratory
tests started to show circulating plasma cells. He was71
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started on VAD chemotherapy (vincristine,
cyclophosphamide, and adriamycin) as his disease
evolved to PCL. An abdominal ultrasound showed
mild hepatosplenomegaly, and skeletal survey con-
ﬁrmed multiple bone lesions.
Laboratory ﬁndings at the time of transformation to
secondary PCL shows white blood counts (WBCs) of
17.10 · 109/L (reference range (RR), 5–10 · 109/L)
with 21% PCs, hemoglobin (HGB) level of 78 g/L
(RR, 140–180 g/L), and platelets (PLT) were
62 · 109/L (RR, 150–450 · 109/L). Other laboratory
studies included serum creatinine of 141 lmol/L (RR,
46–115 lmol/L); Ca, 2.26 mmol/L (RR, 2.1–2.55
mmol/L); lactate dehydrogenase (LDH), 407 U/L
(RR, 135–225 U/L); and b2-microglobulin,
5.58 mg/L (RR, 0.7–1.8 mg/L). Serum protein elec-
trophoresis (SsPE) and immunoﬁxation revealed
IgG-kappa with 75.5% M-spike of total protein and
99.2% of total gamma globulin. Urinalysis was positive
for Bence Jones protein (BJ protein).
Bone marrow (BM) examination demonstrated
diffuse involvement by more than 80% PCs, of which
some were binuclear and few had prominent nucleoli.
Flow cytometry showed that PCs were positive for
CD138, CD38, CD56 and cytoplasmic Kappa.
Cytogenetic analysis revealed complex karyotyping
of 45,XY,+i(1)(q10),add(2)(q33),add(6)(q23),t(8;14)
(p21;q32),-11,t(12;22)(p13;q13),-13,-14, add(19)
(q13.4),+22[cp4]/46,XY[9].
The patient continued receiving VAD, but had no
response, and PCs in the peripheral blood ﬂuctuated
between 30% and 45%. The patient ultimately died
from refractory plasma cell dyscrasia progression,
10 months after diagnosis of PCL.
Case 2
A 71-year-old female patient presented with lower
back pain, generalized weakness, and severe anemia.
She was known to have hypertension, diabetes melli-
tus (type 2), hyperlipidemia and severe coronary
artery disease with ejection fraction of 66%; status
post cardiac catheterization. Eleven years ago, she
was diagnosed with left breast cancer and received
5000 cGy of radiotherapy to the left breast over a per-
iod of three months. She had multiple lytic lesions
noted by skull X-ray unrelated to her breast cancer
as there was no evidence of disease activity elsewhere
and skeletal survey showed generalized osteopenia
(Image 1). No evidence of organomegaly was detected.
Laboratory studies revealed a WBC count of
7.15 · 109/L with 35% circulating PCs, HGB level
of 76 g/L and PLT count was 78 · 109/L. Serum
creatinine was 102 lmol/L Ca 2.11 mmol/L andb2-microglobulin 6.04 mg/L. SPE revealed a
hypogammaglobulinemia, and urine protein elec-
trophoresis (UPE) was negative. BM examination
showed diffuse inﬁltration by atypical lymphoid cells
that accounted for about 40–50% of all nucleated
cells. These cells were identiﬁed as PCs or lympho-
plasmacytoid cells, which have very irregular cytoplas-
mic borders with eccentric nuclei and prominent
nucleoli, with some showing cytoplasmic vacuolation.
Flow cytometry conﬁrmed that 55% of all cells were
positive for CD38, CD138, and cytoplasmic Kappa,
while negative for CD45 and CD56. This ﬂow cytom-
etry result is consistent with plasma cell dyscrasia.
Fluorescent in situ hybridization (FISH) was positive,
and in which 99% of 200 examined cells had both
13q14 and 13q34 deletion, reﬂecting 13. Also,
96% of the cells had trisomy ATM, indicating partial
or complete trisomy for chromosome 11.
Because of her age, comorbid diseases, and heart
failure, she was offered melphalan, dexamethasone,
weekly doses of erythropoietin, and was continued
on palliative treatment. She was lost to follow up,
and most likely succumbed to her disease.
Case 3
A 53-year-old male patient was referred with anemia,
thrombocytopenia, leukocytosis, and mild renal
impairment. His abdominal ultrasound revealed a
mild splenomegaly and skeletal survey demonstrated
a well-deﬁned lytic lesion seen at the right aspect of
the occipital bone with collapsed T9 vertebral body.
A complete blood count at the time of referral showed
a WBC count of 16.15 · 109/L with 24% circulating
PCs, HGB level of 96 g/L and platelet count was
10 · 109/L. Other laboratory studies included serum
creatinine which was 309 lmol/L, calcium
2.55 mmol/L, and b2-microglobulin 17.10 mg/L.
SPE revealed borderline hypogammaglobulinemia,
and UPE was negative. The BM was diffusely inﬁl-
trated with PCs and some lymphoplasmacytoid cells
which accounted for 30–40% (Image 2). Flow cytom-
etry showed 26% monoclonal PCs with positivity for
CD38, CD138, cytoplasmic Kappa, and negativity for
DC56 and CD45. FISH was positive for deletion of
both 13q14 and 13q34, suggesting –13, and 76%
had IGH rearrangement; however, CCND1 (cyclin
D1) was ruled out as fusion partner.
The patient received six cycles of Velcade/
dexamethasone chemotherapy and achieved complete
remission. He was mobilized for autologous stem cell
transplantation (SCT) with cyclophosphamide and
G-CSF protocol, and then received high dose melpha-
lan and peripheral blood SCT. He was discharged in aHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
Image 2. BM aspirate and biopsy for cases 3 and 4. A. BM aspirate for case 3 appeared diffusely infiltrated with PCs and some
lymphoplasmacytoid (Wright-Giemsa stain ·100). B. BM biopsy for case 3 showing a sheet of plasma cells with the characteristic cogwheel
chromatin arrangement (H&E stain ·100). C. BM aspirate for case 4 markedly infiltrated by pleomorphic plasma cells (Wright-Giemsa stain ·100).
D. BM biopsy for case 4 showing many plasma cells containing intra-nuclear inclusions (Dutcher bodies `arrows in the image') (H&E stain ·100).
Image 1. Case 2 skull X-ray showing multiple lytic lesions involving the skull vault, mainly the left parietal region.
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good condition after he recovered his peripheral blood
on day 15 post-transplant. In his last outpatient clinic
visit, he was still pancytopenic with WBC count of
2.29 · 109/L, HGB of 70 g/L and PLT was
43 · 109/L with no PCs in the peripheral blood. His
creatinine had normalized to 106 lmol/L, Ca to
2.11 mmol/L, but his b2-microglobulin was
7.72 mg/L.
The patient was still alive and in a good condition
three years after auto-SCT and until the time this
manuscript was written.
Case 4
A 70-year-old female patient was admitted with gen-
eralized bone pain over a period of about two weeks,
weight loss, and renal impairment. She had a history
of rheumatic heart mitral stenosis and aortic stenosis.
She was on warfarin for chronic atrial ﬁbrillation.
Radiologically, the patient was found to have hep-
atomegaly with no deﬁnite osteolytic lesions; however,
diffuse osteopenia was noted.
At time of referral, WBC was 18.24 · 109/L with
66% circulating PCs, HGB 78 g/L, and PLT was
85 · 109/L. Other laboratory studies included serum
creatinine that was 187 lmol/L and calcium at
2.01 mmol/L. Testing for b2-microglobulin was not
available. Serum protein electrophoresis and
immunoﬁxation revealed IgG-kappa (M-spike) of
51.4% of total serum proteins, and 92.3% of total
gamma globulins (=58.60 g/L). UPE was positive
for IgG-kappa and free kappa light chain monoclonal
gammopathy.
The BM was markedly inﬁltrated by pleomorphic
plasma cells of more than 90% (Image 1). Flow
cytometry analysis revealed more than 55% clonal
plasma cells with positivity for CD38, CD138, and
cKappa. CD56 and CD45 were negative.
Chromosomal analysis could not be carried out
because very few dividing cells were available, but
FISH study was negative.
The patient was diagnosed with primary PCL and
referred back to her local hospital with an arrange-
ment to receive weekly Velcade 1.3 mg/m2 and dex-
amethasone 20 mg weekly.DISCUSSION
PCL needs to be diagnosed in a timely manner to
immediately initiate therapy. The incidence of PCL
ranges between 2–4% of patients with MM and
0.9% of patients with acute leukemia.5,6 The clinical
and laboratory results for all four cases are summa-
rized in Table 1. Three out of the four cases wereprimary PCL and one case was secondary.
Secondary PCL occurs as a progression of disease in
1–4% of all cases of MM.7 The biology of dissemina-
tion of tumor cells out of the BM is not only related
to changes in expression of adhesion molecules and
chemokine receptors but also to the presence of sev-
eral molecular aberrations, which contribute to BM
microenvironment-independent tumor growth, inhi-
bition of apoptosis, and escape from immune
surveillance.4
It has been reported that male to female sex distri-
bution in both primary and secondary PCL are 3:2.8
The male to female ratio was equal (1:1) in our
patients and the age range was 52–70 years.
Up to 15% of PCL patients will have hep-
atomegaly, splenomegaly or lymphadenopathy.7
Three out of our four patients had either hep-
atomegaly and/or splenomegaly, where none of the
patients showed relevant lymphadenopathy. Bone
lytic lesions were observed in three cases, and two
cases were reported to have generalized osteopenia.
The majority of patients with PCL do not have
clinical evidence of overt bone destruction and,
because of extensive involvement of the bone marrow,
they tend to show a higher prevalence of anemia and
thrombocytopenia. This is evident in all of our
patients with 78 g/L and 70 · 109/L median hemo-
globin level and platelets counts, respectively, at
diagnosis.2,8,9
Other laboratory ﬁndings include a higher preva-
lence of renal insufﬁciency, elevated b2-
microglobulin and elevated LDH. In three out of
our four cases, there was renal insufﬁciency; three
tested patients showed high b2-microglobulin; and
two out of three tested cases revealed high LDH.
Peripheral blood examination in PCL should show
circulating tumor cells, and typically a leukoerythrob-
lastic blood picture in up to 67% of patients.8 BM
biopsy typically demonstrates extensive BM involve-
ment by PCs that disrupt the normal hematopoiesis.
In some cases, the tumor cells resemble normal
plasma cells with basophilic cytoplasm, prominent
Golgi zone, and eccentric nuclei. Other cases have
many lymphoplasmacytoid lymphocytes and only a
minority of characteristic plasma cells as in case 2.
Yet others have more primitive cells with a higher
nuclear cytoplasmic ratio, open chromatin, prominent
nucleoli, and a less prominent Golgi zone (plas-
mablasts).10 Sometimes, circulating plasma cells are
difﬁcult to classify by light microscopy alone, and dif-
ferentiation from other conditions requires
immunophenotypic analysis, which can also be useful
to differentiate reactive from clonal plasma cells. TheHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
Table 1. Characteristics of the four PCL patients.
Case 1 Case 2 Case 3 Case 4 Median
PCL type Secondary Primary Primary Primary
Sex Male Female Male Female
Age (y) 52 70 53 70 52
Organomegaly Hepatosplenomegaly No organomegaly Mild splenomegaly Hepatomegaly
Bone lesion Multiple lytic lesions Multiple lytic lesions in the
skull &
generalized osteopenia
Well defined lytic lesions seen at
the right
aspect of the occipital bone
Diffuse osteopenia but no
osteolytic lesions
Ca, Total (mmol/L) N
(2.1–2.55)
2.26 2.11 2.55 2.01 2.18
Creatinine (lmol/L)
N (46–115)
141 102 309 187 164
LDH (U/L) N (135–
225)00
407 NA 412 157 407
Serum Protein
Electropheresis
IgG-kappa Hypogammablobulinemia Hypogammaglobulinemia IgG-kappa
Urine Protein
Electrophoresis
IgG-kappa Trace of albumin is present No proteinuria IgG-kappa and free kappa
light chain
monoclonal gammopathy
b2microglobulin (mg/
L) N (0.7–1.80)00
5.58 6.04 17.10 NA 6.04
WBC (109/L) 17.10 7.95 16.15 18.24 16.6
Hg (g/L) 78 76 96 78 78
PLT (109/L) 62 78 10 85 70
PCs in PB (%) 21 35 24 66 29
PCs in BM (%) 80 55 35 90 67
Immuno-phenotyping CD38+,CD138+,CD56+,
cKappa+, CD45-, CD20-
CD38+,CD138+,
cKappa+, DC56,
CD45-, CD20-
CD38+,CD138+, cKappa+,DC56,
CD45-, CD20-
CD38+,CD138+,
cKappa+,DC56-,
CD45-, CD20-
Cytogenetics 45,XY,+i(1)(q10),
add(2)(q33),add(6)(q23),
t(8;14)(p21;q32),
-11,t(12;22)(p13;q13),-13,-14,
add(19)(q13.4),+22[cp4]/
46,XY[9]
– 13q14 & 13q34 deletion,
reflecting – 13
– Trisomy ATM, indicating
partial or complete tri-
somy
for chromosome 11
– 13q14 &13q34 deletion, sug-
gesting – 13
– Positive for IGH rearrangement
– Too few dividing cells
were
available to establish a
karyotype
– FISH is negative
PCL: plasma cell leukemia; y: year; Ca: Calcium; N: normal; LDH: Lactate Dehydrogenase; NA: not available.
Hematol Oncol Stem Cell Ther 8(2) Second Quarter 2015 75
CASE REPORTS OF PLASMA CELL LEUKEMIA brief communication
76
brief communication CASE REPORTS OF PLASMA CELL LEUKEMIA
peripheral blood smear in all cases showed more than
20% circulating plasma cells, which, by deﬁnition, is
the percentage needed to diagnose PCL.1 Moreover,
the BM was diffusely inﬁltrated by plasma cells dis-
rupting normal hematopoiesis. The plasma cells dis-
played a spectrum of maturity, from small mature
plasma cells to large, anaplastic, blastic or lymphoplas-
macytic cells that were difﬁcult to classify (Image 2).
Flow cytometry analysis using CD38 and CD138
antigen expression is an excellent PC marker.
However, it does not differentiate between MM and
PCL. Typically, primary PCL tumor cells are more
likely to express CD20, CD45, CD19, CD27, and
CD23, while CD56, CD71, CD117, and HLA-DR
are less often positive.4,9 Flow cytometry immunophe-
notyping examination for our patients was positive for
plasma cell associated antigen CD38 and CD138 and
non-expressed B cell associated antigen (CD19 or
CD20).
Compared with MM, tumor cells from primary
and secondary PCL patients have reduced expression
of the adhesion molecules NCAM (neural cell adhe-
sion molecule/CD56) and LFA-1 (leukocyte
function-associated antigen-1), which may contribute
to the extramedullary accumulation of tumor cells in
PCL.9,11 Kraj et al. compared primary and secondary
PCL and found that their immunophenotypic proﬁles
were comparable, except for CD56 expression, which
was more often present in secondary PCL, and was
only detected in case 1.11
All four cases expressed monotypic cytoplasmic
immunoglobulin light chain, which is cytoplasmic
Kappa light chain.
Chromosomal and cytogenetic analyses focus on
positivity for hypodiploidy, complex karyotype,
del(17p13), del(13q), del(1p21), ampl(1q21), MYC
translocations or ampliﬁcations, and the presence of
14q32 abnormalities; and they include: t(11;14)
(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23).
Chromosomal and cytogenetic analyses are therefore
highly important for prognostication impact through
their association with reduced OS.4,12 The mostprevalent IgH translocation in primary PCL is
t(11;14) at a frequency of 25–65%, and these translo-
cations are clearly associated with poor
prognosis.8,13,14
In our review, case 1 showed a complex keryotyp-
ing with monosomy 13, and cases 2 and 3 were found
to have FISH results suggestive of monosomy 13
and/or 13q deletion.
Both primary and secondary PCL share a poor
prognosis. Most series report a median survival not
exceeding one year.1,9 The use of more intensive
chemotherapy and SCT lead to a 20-month median
survival.8
In conclusion, PCL is a rare disease, and this was
conﬁrmed by our study. It is an aggressive form of
plasma cell dyscrasias carrying a poor prognosis
despite intensive chemotherapy, SCT, and the use
of novel anti-myeloma agents. The morphology of
the plasma cell could be highly misleading, and for
that reason, comprehensive workup by immunophe-
notyping using ﬂow cytometry is crucial for the diag-
nosis of PCL. Cytogenetic workup is substantial for
prognostication. Prospective multicenter studies and
more case reviews are required to reach a better
understanding of the pathogenesis of PCL.COMPETING INTERESTS
The authors declare they have no competing interests.AUTHOR CONTRIBUTIONS
Dr. Nahlah AlGhasham made substantial contribu-
tions to the conception, design and acquisition of
data. Dr. Nahlah and Dr. Randa Alnounou con-
tributed to analysis, interpretation of data and to
drafting the manuscript. Dr. Hazzaa Alzahrani and
Dr. Fahad Alsharif were responsible for the critical
revision of the manuscript’s intellectual content.
All authors read and approved the ﬁnal
manuscript.REFERENCES1. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell
leukemia. Report on 17 cases. Arch Intern Med
1974;133(5):813–8.
2. Noel P, Kyle RA. Plasma cell leukemia: an
evaluation of response to therapy. Am J Med
1987;83(6):1062–8.
3. International Myeloma Working Group. Criteria
for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: a report of
the international myeloma working group. Br J
Haematol 2003;121(5):749–57.4. van de Donk NW, Lokhorst HM, Anderson KC,
Richardson PG. How I treat plasma cell leukemia.
Blood 2012;120(12):2376–89.
5. Fernndez de Larrea C, Kyle RA, Durie BG,
Ludwig H, Usmani S, Vesole DH, et al. Plasma cell
leukemia: consensus statement on diagnostic
requirements, response criteria and treatment rec-
ommendations by the international myeloma work-
ing group. Leukemia 2013;27(4):780–91.
6. Eddou H, Mahtat el M, Zahid H, Maaroufi HE,
Jennane S, Messaoudi N, et al. Plasma cellHematoleukemia: three case-reports and review of litera-
ture. Ann Biol Clin (Paris) 2013;71(6):698–702.
7. Blad J, Kyle RA. Nonsecretory myeloma,
immunoglobulin D myeloma, and plasma cell
leukemia. Hematol Oncol Clin North Am
1999;13(6):1259–72.
8. Tiedemann RE, Gonzalez-Paz N, Kyle RA,
Santana-Davila R, Price-Troska T, Van Wier SA,
et al. Genetic aberrations and survival in plasma
cell leukemia. Leukemia 2008;22(5):1044–52.l Oncol Stem Cell Ther 8(2) Second Quarter 2015
CASE REPORTS OF PLASMA CELL LEUKEMIA brief communication
9. Garca-Sanz R, Orf¼o A, Gonzlez M, Tabernero
MD, Blad J, Moro MJ, et al. Primary plasma cell
leukemia: clinical, immunophenotypic, DNA ploidy,
and cytogenetic characteristics. Blood
1999;93(3):1032–7.
10. Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S,
Anderlini P, Champlin RE, et al. Primary plasma cell
leukemia: morphologic, immunophenotypic, and
cytogenetic features of 4 cases treated with
chemotherapy and stem cell transplantation. Ann
Diagn Pathol 2006;10(5):263–8.Hematol Oncol Stem Cell Ther 8(2) Second Quarter 211. Kraj M, Kopec´-Szle˛zak J, Pogld R, Kruk B. Flow
cytometric immunophenotypic characteristics of 36
cases of plasma cell leukemia. Leuk Res
2011;35(2):169–76.
12. Pagano L, Valentini CG, De Stefano V, Venditti
A, Visani G, Petrucci MT, et al. Primary plasma cell
leukemia: a retrospective multicenter study of 73
patients. Ann Oncol 2011;22(7):1628–35.
13. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-
Bauchi E, Terr C, Lafage-Pochitaloff M, et al.
Cytogenetic, interphase, and multicolor fluorescence015in situ hybridization analyses in primary plasma cell
leukemia: a study of 40 patients at diagnosis, on
behalf of the Intergroupe Francophone du Mylome
and the Groupe FranÅais de Cytogntique
Hmatologique. Blood 2001;97(3):822–5.
14. Avet-Loiseau H, Roussel M, Campion L, Leleu X,
Marit G, Jardel H, et al. Cytogenetic and therapeu-
tic characterization of primary plasma cell leukemia:
the IFM experience. Leukemia 2012;26(1):158–9.77
